Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 1Phase 1 1

Status

Recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Nasopharyngeal Carcinoma 12Esophageal Squamous Cell Carcinoma 3Carcinoma, Transitional Cell 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Recurrence 1Radiotherapy 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1Hodgkin Disease 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Cholangiocarcinoma 1Cervical Cancer Metastatic 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy 1

Interventions

Gemcitabine 12Mitomycin 11Cisplatin 10Carboplatin 8pembrolizumab 7Docetaxel 4toripalimab 3avelumab 3atezolizumab 3Paclitaxel 3sacituzumab govitecan 2disitamab vedotin 2Taxes 2Specimen Handling 2Platinum 2Magnetic Resonance Spectroscopy 2Injections 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1valrubicin 1tislelizumab 1lenvatinib 1eribulin 1epacadostat 1enfortumab vedotin 1durvalumab 1dodecyl maltoside 1Vitamin B 12 1Standard of Care 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Transitional Cell × toripalimab × Clear all
NCT06592326 2024-09-19

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3 Recruiting
460 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

RemeGen Co., Ltd.

Phase 3 Recruiting
452 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT04568304 2020-09-29

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Unknown
364 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡